128 related articles for article (PubMed ID: 31911307)
21. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
22. Discovery of new Syk inhibitors through structure-based virtual screening.
Huang Y; Zhang Y; Fan K; Dong G; Li B; Zhang W; Li J; Sheng C
Bioorg Med Chem Lett; 2017 Apr; 27(8):1776-1779. PubMed ID: 28268139
[TBL] [Abstract][Full Text] [Related]
23. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
24. R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells.
Sun S; Xue D; Chen Z; Ou-Yang Y; Zhang J; Mai J; Gu J; Lu W; Liu X; Liu W; Sheng L; Lu B; Lin Y; Xing F; Chen Z; Mou Y; Yan G; Zhu W; Sai K
Cell Death Dis; 2019 May; 10(5):358. PubMed ID: 31043589
[TBL] [Abstract][Full Text] [Related]
25. Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis.
Clarke AS; Rousseau E; Wang K; Kim JY; Murray BP; Bannister R; Matzkies F; Currie KS; Di Paolo JA
Thromb Res; 2018 Oct; 170():109-118. PubMed ID: 30172129
[TBL] [Abstract][Full Text] [Related]
26. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel Syk/PDGFR-α/c-Kit inhibitors as multi-targeting drugs to treat rheumatoid arthritis.
Li X; Huang Y; Cheng J; Zhang L; Mao F; Zhu J; Sheng C; Li J
Bioorg Med Chem; 2018 Aug; 26(15):4375-4381. PubMed ID: 30078608
[TBL] [Abstract][Full Text] [Related]
28. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
[TBL] [Abstract][Full Text] [Related]
29. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
[TBL] [Abstract][Full Text] [Related]
30. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
Velaparthi U; Wittman M; Liu P; Carboni JM; Lee FY; Attar R; Balimane P; Clarke W; Sinz MW; Hurlburt W; Patel K; Discenza L; Kim S; Gottardis M; Greer A; Li A; Saulnier M; Yang Z; Zimmermann K; Trainor G; Vyas D
J Med Chem; 2008 Oct; 51(19):5897-900. PubMed ID: 18763755
[TBL] [Abstract][Full Text] [Related]
31. Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.
Kaur M; Silakari O
SAR QSAR Environ Res; 2016 Jun; 27(6):469-99. PubMed ID: 27431536
[TBL] [Abstract][Full Text] [Related]
32. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy.
Adams ME; Wallace MB; Kanouni T; Scorah N; O'Connell SM; Miyake H; Shi L; Halkowycz P; Zhang L; Dong Q
Bioorg Med Chem Lett; 2012 Apr; 22(7):2411-4. PubMed ID: 22406151
[TBL] [Abstract][Full Text] [Related]
34. Discovery and SARs of 5-Chloro-
Wang Y; Chen X; Yan Y; Zhu X; Liu M; Liu X
J Med Chem; 2020 Mar; 63(6):3327-3347. PubMed ID: 32129996
[TBL] [Abstract][Full Text] [Related]
35. JTE-852, a novel spleen tyrosine kinase inhibitor, blocks mediator secretion from mast cells with immunoglobulin E crosslinking.
Kato T; Iwasaki H; Kobayashi H; Miyagawa N; Matsuo A; Hata T; Matsushita M
Eur J Pharmacol; 2017 Apr; 801():1-8. PubMed ID: 28259713
[TBL] [Abstract][Full Text] [Related]
36. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors.
Kalogirou AS; East MP; Laitinen T; Torrice CD; Maffuid KA; Drewry DH; Koutentis PA; Johnson GL; Crona DJ; Asquith CRM
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641454
[TBL] [Abstract][Full Text] [Related]
38. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
[TBL] [Abstract][Full Text] [Related]
39. The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain Infarction.
van Eeuwijk JM; Stegner D; Lamb DJ; Kraft P; Beck S; Thielmann I; Kiefer F; Walzog B; Stoll G; Nieswandt B
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1247-53. PubMed ID: 27102960
[TBL] [Abstract][Full Text] [Related]
40. BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells.
Lamb DJ; Wollin SL; Schnapp A; Bischoff D; Erb KJ; Bouyssou T; Guilliard B; Strasser C; Wex E; Blum S; Thaler E; Nickel H; Radmacher O; Haas H; Swantek JL; Souza D; Canfield M; White D; Panzenbeck M; Kashem MA; Sanville-Ross M; Kono T; Sewald K; Braun A; Obernolte H; Danov O; Schaenzle G; Rast G; Maier GM; Hoffmann M
J Pharmacol Exp Ther; 2016 Jun; 357(3):554-61. PubMed ID: 27048659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
